Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2018 16:01 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018

FREMONT, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
May 02, 2018 08:44 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting

FREMONT, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
April 27, 2018 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference

FREMONT, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
April 25, 2018 07:00 ET | Source: Asterias Biotherapeutics

Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2

FREMONT, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
March 15, 2018 16:10 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments

- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2...
March 09, 2018 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018

FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
February 28, 2018 16:10 ET | Source: Asterias Biotherapeutics

Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function - - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into...
February 15, 2018 07:00 ET | Source: Asterias Biotherapeutics

Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program

FREMONT, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat...
January 04, 2018 07:52 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Reports Milestone Targets for 2018

FREMONT, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 2018...
December 19, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study

FREMONT, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment...